These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 29607408)

  • 1. Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial.
    Solowij N; Broyd SJ; Beale C; Prick JA; Greenwood LM; van Hell H; Suo C; Galettis P; Pai N; Fu S; Croft RJ; Martin JH; Yücel M
    Cannabis Cannabinoid Res; 2018; 3(1):21-34. PubMed ID: 29607408
    [No Abstract]   [Full Text] [Related]  

  • 2. Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users.
    Beale C; Broyd SJ; Chye Y; Suo C; Schira M; Galettis P; Martin JH; Yücel M; Solowij N
    Cannabis Cannabinoid Res; 2018; 3(1):94-107. PubMed ID: 29682609
    [No Abstract]   [Full Text] [Related]  

  • 3. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.
    Morgan CJ; Gardener C; Schafer G; Swan S; Demarchi C; Freeman TP; Warrington P; Rupasinghe I; Ramoutar A; Tan N; Wingham G; Lewis S; Curran HV
    Psychol Med; 2012 Feb; 42(2):391-400. PubMed ID: 21798112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daily Cannabidiol Administration for 10 Weeks Modulates Hippocampal and Amygdalar Resting-State Functional Connectivity in Cannabis Users: A Functional Magnetic Resonance Imaging Open-Label Clinical Trial.
    Lorenzetti V; McTavish E; Broyd S; van Hell H; Thomson D; Ganella E; Kottaram AR; Beale C; Martin J; Galettis P; Solowij N; Greenwood LM
    Cannabis Cannabinoid Res; 2023 Jul; ():. PubMed ID: 37603080
    [No Abstract]   [Full Text] [Related]  

  • 6. Brain Imaging Studies on the Cognitive, Pharmacological and Neurobiological Effects of Cannabis in Humans: Evidence from Studies of Adult Users.
    Weinstein A; Livny A; Weizman A
    Curr Pharm Des; 2016; 22(42):6366-6379. PubMed ID: 27549374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition.
    Colizzi M; Bhattacharyya S
    Curr Addict Rep; 2017; 4(2):62-74. PubMed ID: 28580227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder.
    Lees R; Hines LA; Hindocha C; Baio G; Shaban NDC; Stothart G; Mofeez A; Morgan CJA; Curran HV; Freeman TP
    Psychopharmacology (Berl); 2023 Feb; 240(2):337-346. PubMed ID: 36598543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.
    Englund A; Morrison PD; Nottage J; Hague D; Kane F; Bonaccorso S; Stone JM; Reichenberg A; Brenneisen R; Holt D; Feilding A; Walker L; Murray RM; Kapur S
    J Psychopharmacol; 2013 Jan; 27(1):19-27. PubMed ID: 23042808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute effects of cannabis on speech illusions and psychotic-like symptoms: two studies testing the moderating effects of cannabidiol and adolescence.
    Mokrysz C; Shaban NDC; Freeman TP; Lawn W; Pope RA; Hindocha C; Freeman A; Wall MB; Bloomfield MAP; Morgan CJA; Nutt DJ; Curran HV
    Psychol Med; 2021 Sep; 51(12):2134-2142. PubMed ID: 32340632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.
    Haney M; Malcolm RJ; Babalonis S; Nuzzo PA; Cooper ZD; Bedi G; Gray KM; McRae-Clark A; Lofwall MR; Sparenborg S; Walsh SL
    Neuropsychopharmacology; 2016 Jul; 41(8):1974-82. PubMed ID: 26708108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hippocampal harms, protection and recovery following regular cannabis use.
    Yücel M; Lorenzetti V; Suo C; Zalesky A; Fornito A; Takagi MJ; Lubman DI; Solowij N
    Transl Psychiatry; 2016 Jan; 6(1):e710. PubMed ID: 26756903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers.
    Woelfl T; Rohleder C; Mueller JK; Lange B; Reuter A; Schmidt AM; Koethe D; Hellmich M; Leweke FM
    Front Psychiatry; 2020; 11():576877. PubMed ID: 33304282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
    Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
    Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
    Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
    Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study: a phase 1 dosage escalation study.
    Reithmeier D; Tang-Wai R; Seifert B; Lyon AW; Alcorn J; Acton B; Corley S; Prosser-Loose E; Mousseau DD; Lim HJ; Tellez-Zenteno J; Huh L; Leung E; Carmant L; Huntsman RJ
    BMC Pediatr; 2018 Jul; 18(1):221. PubMed ID: 29981580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia.
    Osborne AL; Solowij N; Weston-Green K
    Neurosci Biobehav Rev; 2017 Jan; 72():310-324. PubMed ID: 27884751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of the antipsychotic properties of cannabidiol in humans.
    Iseger TA; Bossong MG
    Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
    Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.